2014-2018年美国新诊断HIV-1感染者传播性耐药监测
结果显示18.9%存在至少一种TDRM,INSTI类耐药率最低(0.8%),NNRTI类最高(12.0%),总体及各药物类别耐药率保持稳定,仅M184V呈逐年上升趋势。
要点
- 新诊断HIV感染者中18.9%携带至少一种传播性耐药突变。
- INSTI类传播性耐药率低(0.8%),NNRTI类最高(12.0%)。
- M184V突变每年增加12.9%,需持续监测。
核心结论
- 2014-2018年美国新诊断HIV感染者中传播性耐药突变总体及各药物类别流行率保持稳定。
- 传播性INSTI耐药不常见,但M184V呈显著逐年上升趋势。
研究设计与样本
- 分析美国国家HIV监测系统中2014-2018年新诊断且诊断后≤3个月内完成耐药检测者的数据。
主要发现
- TDRM流行率:INSTI为0.8%,蛋白酶抑制剂为4.2%,NRTI为6.9%,NNRTI为12.0%。
- K103N最常见(8.6%),M184V为0.9%,K65R为0.1%。
- 2014-2018年总体、各药物类别及关键单个突变流行率无显著升降,仅M184V每年增加12.9%(95%CI 5.6-20.6%)。
关键数值与推荐
- 美国推荐在进入HIV关怀时进行耐药检测。
- 纳入分析的条件为诊断后≤3个月内完成耐药检测并报告至国家HIV监测系统。
- 纳入辖区需在该期间≥20%的HIV诊断有合格序列。
临床怎么用
- 支持新诊断HIV感染者进入关怀时常规进行耐药检测以指导临床决策。
- 在第二代INSTI和PrEP扩大使用背景下,需持续开展人群水平的INSTI和NRTI突变监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transmitted human immunodeficiency virus (HIV) drug resistance can threaten the efficacy of antiretroviral therapy and pre-exposure prophylaxis (PrEP). Drug-resistance testing is recommended at entry to HIV care in the United States and provides valuable insight for clinical decision making and population-level monitoring. METHODS: We assessed transmitted drug-resistance-associated mutation (TDRM) prevalence and predicted susceptibility to common HIV drugs among US persons with HIV diagnosed during 2014-2018 who had a drug resistance test performed ≤3 months after HIV diagnosis and reported to the National HIV Surveillance System and who resided in 28 jurisdictions where ≥20% of HIV diagnoses had an eligible sequence during this period. RESULTS: Of 50 747 persons in the analysis, 9616 (18.9%) had ≥1 TDRM. TDRM prevalence was 0.8% for integrase strand transfer inhibitors (INSTIs), 4.2% for protease inhibitors, 6.9% for nucleoside reverse transcriptase inhibitors (NRTIs), and 12.0% for non-NRTIs. Most individual mutations had a prevalence <1.0% including M184V (0.9%) and K65R (0.1%); K103N was most prevalent (8.6%). TDRM prevalence did not increase or decrease significantly during 2014-2018 overall, for individual drug classes, or for key individual mutations except for M184V (12.9% increase per year; 95% confidence interval, 5.6-20.6%). CONCLUSIONS: TDRM prevalence overall and for individual drug classes remained stable during 2014-2018; transmitted INSTI resistance was uncommon. Continued population-level monitoring of INSTI and NRTI mutations, especially M184V and K65R, is warranted amidst expanding use of second-generation INSTIs and PrEP.
引用
- McClung RP, Oster AM, Ocfemia MCB, et al. Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018. Clin Infect Dis. 2022. PMID: 34175948. doi:10.1093/cid/ciab583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。